Conference Highlights

The evolution of precision medicine has transformed oncology, offering targeted treatment strategies tailored to individual patients. However, for many healthcare practitioners, effectively applying precision medicine in clinical practice remains a significant challenge. Read More ›

A peer navigation model that addresses barriers in clinical trial participation and aims to boost enrollment in childhood cancer therapeutic clinical trials is underway, and one of the study researchers presented on the model at the 66th American Society of Hematology Annual Meeting & Exposition, held recently in San Diego, CA. Read More ›

A recent US-based study presented at the San Antonio Breast Cancer Symposium examined racial disparities in biomarker prevalence, treatment patterns, and clinical outcomes among Black and White patients with hormone receptor-positive/HER2-negative metastatic breast cancer who underwent next-generation sequencing. Read More ›

Clinical practice has evolved over time, and the doctor’s tools used in the past may no longer be the tools that are regularly utilized today. However, that brings up the question: what tools will healthcare utilize today or in the future? Read More ›

Next-generation sequencing of circulating tumor DNA (ctDNA) is integral to optimal cancer treatment, as exploring ctDNA can provide a complete picture of a tumor’s genetic landscape and can thus help guide treatment for the patient. The IMAGE II study (NCT02965755) investigated the clinical utility of serial ctDNA assessment in patients with metastatic breast cancer. Read More ›

Machine learning may hold promise for analyzing cells co-expressing MYC and BCL2 but lacking BCL6 in diffuse large B-cell lymphoma, which can be associated with poorer survival patterns, according to a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›

Later cancer treatment initiation and fewer treatment options once treatment starts are just some of the impacts of longer driving distances to treatment, according to researchers reporting in a study presented at the 66th Annual Meeting & Exposition held in San Diego, CA. Read More ›

Patients diagnosed with high-risk multiple myeloma persistently exhibit markedly inferior survival rates compared with patients without high-risk disease, despite the advancements in novel therapeutic agents available today. Read More ›

The intravenous administration of the anti-CD38 antibody isatuximab, in conjunction with pomalidomide and dexamethasone, has received approval for the treatment of patients with relapsed or refractory multiple myeloma (RRMM), as established by the findings of the ICARIA-MM study (NCT02990338) and presented at the International Myeloma Society 21st Annual Meeting & Exposition. Read More ›

Bortezomib in combination with lenalidomide and dexamethasone (VRd) represents a standard initial treatment option for both transplant-eligible and -ineligible patients with multiple myeloma, according to study findings that were presented at the 21st International Myeloma Society Annual Meeting. Read More ›